STOCKHOLM, May 22, 2022
/PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq
Stockholm: CANTA) today reported new preclinical results,
demonstrating efficacy of the IL1RAP-binding antibody CAN10 in a
preclinical disease model for atherosclerosis. Treatment with a
CAN10 surrogate antibody reduced plaque burden and plaque
inflammation in this model, supporting the potential of CAN10 as a
potent therapeutic in cardiovascular disease. These findings will
be presented at the European Atherosclerosis Society (EAS) Congress
in Milan on 22-25 May.
"These new results highlight the potential of CAN10 in
various inflammatory diseases and identifies new opportunities in
cardiovascular disease, beyond our current focus on myocarditis and
systemic sclerosis. In parallel with the continuing progress of our
lead product nadunolimab in multiple indications in cancer, we are
looking forward to the first human trial of CAN10 in early
2023," said Göran Forsberg, CEO of Cantargia.
CAN10 is an antibody that has demonstrated potent
anti-inflammatory effects by binding IL1RAP (Interleukin-1 Receptor
Accessory Protein). Cantargia is developing CAN10 for treatment of
inflammatory and autoimmune disease with an initial focus on
myocarditis and systemic sclerosis.
The data presented at the EAS Congress show high levels of
IL1RAP in the atherosclerotic plaques in a preclinical model.
Treatment with a CAN10 surrogate antibody reduced the aortic plaque
burden and number of infiltrating inflammatory cells in the plaques
in this model. This strongly suggests that IL1RAP blockade has a
positive effect on atherosclerosis and plaque inflammation,
supporting the idea that IL1RAP represents a novel therapeutic
target in this disease. These latest data on CAN10 were generated
in collaboration with the research group at Lund University
Cardiovascular Research Unit led by Dr. Daniel Engelbertsen.
"Inflammation is considered a driver of plaque formation and
their instability which can lead to plaque disruption and
infarction. Our studies suggest that IL1RAP signaling is involved
in the development of atherosclerosis and that blockade of IL1RAP
using the CAN10 antibody may have positive effects on different
aspects of the disease," said Dr. Daniel Engelbertsen.
The new CAN10 results will be presented as a poster at the EAS
Congress and highlighted in a poster discussion session with an
oral presentation. The poster will be made available on Cantargia's
webpage
(https://cantargia.com/en/research-development/publications) after
the presentation on 24 May.
CAN10 blocks the function of IL1RAP in a different manner than
nadunolimab (CAN04), Cantargia's anti-cancer antibody asset. CAN10
strongly binds IL1RAP and functions by simultaneous blockade of
IL-1, IL-33 and IL-36 signaling, which can be of significant value
in the treatment of several autoimmune or inflammatory diseases.
CAN10 has previously shown potent effects in several models of
inflammation, including myocarditis and systemic sclerosis.
Cantargia plans to initiate clinical phase I studies for CAN10 in
early 2023.
For further information, please contact:
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This is information that Cantargia AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, at 09.00 CET on 22 May
2022.
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology
company that develops antibody-based treatments for
life-threatening diseases and has established a platform based on
the protein IL1RAP, involved in a number of cancer forms and
inflammatory diseases. The lead project, the antibody nadunolimab
(CAN04), is being studied clinically in combination with
chemotherapy or immune therapy in a series of clinical studies –
CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR – with a primary
focus on non-small cell lung cancer and pancreatic cancer. Positive
interim data from the combination with chemotherapy indicate
stronger efficacy than would be expected from chemotherapy alone.
Cantargia's second project, the antibody CAN10, blocks signaling
via IL1RAP in a different manner than nadunolimab and addresses
treatment of serious autoimmune/inflammatory diseases, with initial
focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More
information about Cantargia is available at
https://cantargia.com/en/.
About CAN10
The CAN10 antibody binds strongly to its target IL1RAP and has a
unique capability to simultaneously inhibit signaling via IL-1,
IL-33 and IL-36. Inhibition of these signals can be of significant
value in the treatment of several inflammatory or autoimmune
diseases. The initial focus of CAN10 will be on two severe
diseases: myocarditis and systemic sclerosis. In a preclinical in
vivo model of myocarditis, a CAN10 surrogate antibody significantly
reduced the development of inflammation and fibrosis, and
significantly counteracted the deterioration of the cardiac
function. CAN10 also inhibited disease development in models of
systemic sclerosis, peritonitis, psoriasis and psoriatic arthritis.
CAN10 is currently in late-stage preclinical development and the
first clinical trial is expected to begin in early 2023.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/cantargia-ab/r/cantargia-reports-positive-preclinical-effects-in-atherosclerosis-demonstrating-potential-of-can10-i,c3571281
The following files are available for download:
https://mb.cision.com/Main/7470/3571281/1582507.pdf
|
EAS CAN10 poster Eng
220522 Final
|